<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326156</url>
  </required_header>
  <id_info>
    <org_study_id>56789</org_study_id>
    <nct_id>NCT01326156</nct_id>
  </id_info>
  <brief_title>Study of Knee Replacements for Patellofemoral Osteoarthritis</brief_title>
  <acronym>PFA/TKR</acronym>
  <official_title>Patellofemoral Arthroplasty (PFA) Versus Total Knee Replacement (TKR) for Isolated Patellofemoral Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Nordic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DePuy Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized comparison of PFA and TKR in treatment of isolated patellofemoral&#xD;
      osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Isolated patellofemoral osteoarthritis can be a disabling condition of the knee necessitating&#xD;
      knee arthroplasty. It is debated whether total knee replacement or isolated patellofemoral&#xD;
      replacement is the better treatment option. This randomized trial attempts to give a&#xD;
      qualified answer to the debate by comparing clinical outcome (range of movement, stability,&#xD;
      effusion, patellofemoral tracking, tenderness, stair climbing), patient self assessment&#xD;
      scores (EQ-5D, Oxford Knee Score, KOOS, SF-36, AKS), complications (infections, revisions),&#xD;
      longevity (survival analysis) and cost (direct and indirect) for the two implant types.&#xD;
&#xD;
      The Avon patellofemoral implant has been chosen, as this is the patellofemoral implant with&#xD;
      the best documentation. The PFC Sigma CR total knee implant has been chosen as it a current&#xD;
      standard implant and market leader.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported outcomes (disease-specific and generic QoL instruments)</measure>
    <time_frame>10 years</time_frame>
    <description>The physical functioning score of the Short Form (36) Health Survey is the primary outcome measure of the study. Disease-specific patient-reported outcomes (Oxford Knee Score, KOOS and Kujala) and a second generic quality of life measure (EQ5D).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant survival, clinician assessment and cost.</measure>
    <time_frame>10 years</time_frame>
    <description>Secondary outcome measures relate to implant survival, clinician assessment and cost. Implant survival will be assessed by 5- and 10-year implant survival rates and by analyzing causes for revision surgery. Clinician assessment includes Knee Society Score (stability, range of movement, effusion, tenderness etc.). Assessments of immediate and long-term costs are based on patient diaries, sick leave, use of medical services and drug prescriptions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Avon patellofemoral replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Knee arthroplasty with insertion of patellofemoral joint replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFC Sigma CR total knee replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Knee arthroplasty with total (tricompartmental) knee replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Knee arthroplasty</intervention_name>
    <description>Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.</description>
    <arm_group_label>Avon patellofemoral replacement</arm_group_label>
    <arm_group_label>PFC Sigma CR total knee replacement</arm_group_label>
    <other_name>PFA: Avon Patellofemoal arthroplasty (Stryker)</other_name>
    <other_name>TKR: PFC Sigma CR arthroplasty (DePuy)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Isolated PF-OA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medial or lateral OA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Odgaard, FRCS, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Orthopaedics, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Knee cap</keyword>
  <keyword>Patella</keyword>
  <keyword>Patellofemoral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD that underlie the results reported in published article, after deidentification (text, tables, figures and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 6 months and and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>For investigators whose proposed use of the data has been approved by and independent review committee identified for this purpose or for researchers who provide a methdologically sound proposal.&#xD;
Types of analyses accepted: For acheiving aims of the approved proposal.&#xD;
Proposals should be directed to anders.odgaard@regionh.dk. To gain access, data requestors will need to sign a data access agreement. Data will be available for 5 years following publication at a third party website.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

